RICHMOND, Ca--Onyx Pharmaceuticals has announced an extension
and expansion of its research alliance with Eli Lilly focusing
on BRCA1, the gene linked to increased risk of breast and ovarian
cancer. Lilly has exclusive rights to the BRCA1 gene by license
from Myriad Genetics, Inc.
The collaboration, originally begun in May 1995, aims to understand
the role of BRCA1-related pathways in breast cancer and to identify
proteins that interact with the gene that could be used to develop